AbbVie Inc. /zigman2/quotes/202428675/composite ABBV +0.37% , Amgen Inc. /zigman2/quotes/209157011/composite AMGN +1.46% , and Takeda Pharmaceutical Co. Ltd. /zigman2/quotes/204098703/composite TAK 0.00% announced they started enrolling patients in a clinical trial testing three of their drugs as treatments for severely ill and hospitalized COVID-19 patients. This includes the still investigational HIV therapy cenicriviroc, psoriasis medication Otezla, and the anti-inflammatory drug Firazyr. The companies are using a platform aimed at minimizing the number of clinical-trial participants and the time it takes to test those drugs under an umbrella group called the COVID R&D Alliance. Since the start of the year, AbbVie's stock is up 7.2%, shares of Amgen have gained 1.5%, and Takeda's stock is down 7.4%. The S&P 500 /zigman2/quotes/210599714/realtime SPX +1.60% is up 1.2%.